Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDwZWs1QCCq MXnJR|UxRTF|OT6yNQKBkcLz4pEJOU46PSEQvF2= M1PaNVI2QTZyMkiy
KellyCis83 Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV20PEBp NG\aPXFKSzVyPUK1NU4xOOLCidMx5qCKOTVwN{Wg{txO M1XYR|I2QTZyMkiy
SK-N-AS NVy1THJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe0PEBp Mon0TWM2OD1{MkeuO|DjiIoEsfMAjVIzNjF3IN88US=> MmfnNlU6PjB{OEK=
SK-N-ASCis24 M1Luc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO0PEBp NXi3emhmUUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? M2T4fFI2QTZyMkiy
CHP-212 NEP0SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHrdGo1QCCq NV3NeFFjUUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=> NGX1c|QzPTl4MEK4Ni=>
CHP-212Cis100 MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrUNJhuPDhiaB?= NYTPUYFMUUN3ME25MlU26oDLwsJihKkxNjh6IN88US=> MXKyOVk3ODJ6Mh?=
U87  MkTlSpVv[3Srb36gRZN{[Xl? NHrpRWsyODBizszN NGfjbHIzPC15MjDo MkTmbY5lfWOnczDEZ3IyKGW6cILld5Nqd25? NWHBU5F5OjV6MEi4Olg>
LN229 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXhbVAxNTVyIN88US=> M3i5SGlEPTB;MU[g{txO NWizepRzOjV5NUCyO|M>
TR-LN229 NHzuSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;mNE02OCEQvF2= Mk\QTWM2OD15NzFOwG0> MWiyOVc2ODJ5Mx?=
U87  MmO0RZBweHSxc3nzJGF{e2G7 MYmw5qCUOjBy4pEJxtVO M4fWS|I1KGh? NEi3XHVmdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>? NIP0O3czPTZ6MU[2PC=>
U251MG NV7kUoNbSXCxcITvd4l{KEG|c3H5 MUCxNFDDqM7:TR?= NGHkU4M1QCCq NFK4bVJRSlN? M4ToT4lv\HWlZYOgZZBweHSxc3nz M4fhR|I2PjhyNE[0
U87MG NHTqPHVCeG:ydH;zbZMhSXO|YYm= M1LOVFExOMLizszN M{D1XlQ5KGh? M4\GbnBDWw>? MnLHbY5lfWOnczDhdI9xfG:|aYO= MXiyOVY5ODR4NB?=
U87 NHf5U|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfScpF1PTBvM{WwJO69VQ>? MX60POKhcMLi NUDEXmt4cW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? M1;FN|I2PTV2MkKz
U118  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnMcWF7PTBvM{WwJO69VQ>? MUi0POKhcMLi MXvpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> NIXo[ZAzPTV3NEKyNy=>
U87 NULqTlY1TnWwY4Tpc44hSXO|YYm= MYeyOVAwOzVyIN88US=> MmHXOFjDqGkEoB?= M1vxNoVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? NYLGNmRDOjV3NUSyNlM>
U118  M2foS2Z2dmO2aX;uJGF{e2G7 M1;pbVI2OC9|NUCg{txO MVm0POKhcMLi MX3lcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U> NGrvbXAzPTV3NEKyNy=>
U87 MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOyOVAwOzVyIN88US=> NFL2OXo1QMLiaNMg M2fUR4lv[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuczDpckBUKGGwZDDHNk9OyqClb4Ty[YF1\WRid3n0bEBVVVh? MX6yOVU2PDJ{Mx?=
A375 M1jQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrDRVU1QMLiaNMg Mn7zTWM2OD1{NkWg{txO MV2yOVUzPDV3Mh?=
A2058 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHjTY01QMLiaNMg MYfJR|UxRTF{IN88US=> NYPLOWdTOjV3MkS1OVI>
M238 NXPiUWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom4OFjDqGkEoB?= NVnGfWR2UUN3ME20NEDPxE1? NWnUcYFlOjV3MkS1OVI>
M249 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Pe281QMLiaNMg NYnmV2JmUUN3ME2yOVQh|ryP NGDu[ZEzPTV{NEW1Ni=>
M21 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYS0POKhcMLi M3vuWGlEPTB;MkKxJO69VQ>? NITMTIkzPTV{NEW1Ni=>
U251 NFvnSVNEgXSxdH;4bZR6KEG|c3H5 Mn62NlAh|ryPwrC= M33FN|Q5yqCqwrC= NVfqTm5TemWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> NUPGc|FkOjV2M{SzPFE>
LN229 MljrR5l1d3SxeHn0fUBCe3OjeR?= M4DUOlIxKM7:TdMg Mn\TOFjDqGkEoB?= NHW2eG5z\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk MWSyOVQ{PDN6MR?=
U373MG-LUC MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\HO|IhcA>? MWHJR|UxRjZyMDFOwG0> Ml74NlU1OzF7NUO=
U87  M{HFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjTbWkzPS1{MECg{txO MlrTOFjDqGkEoB?= MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{LMUlI2PDByN{S1
U251 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D5R|I2NTJyMDFOwG0> NFnvUnE1QMLiaNMg NYLucI9mcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXjqOm1GOjV2MEC3OFU>
U251 M4Xpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDNNVAxNTRyMDFOwG0> MmXaO|IwQTZiaB?= NIX3d4Z1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= MWqyOVM4PTJ5MR?=
U373 NXzZd5prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyNVAxNTRyMDFOwG0> MnPPO|IwQTZiaB?= M4fzR5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MkTCNlU{PzV{N{G=
U343 NVG1UJRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrSZZJmOTByLUSwNEDPxE1? NIPLcWI4Oi97NjDo M4rWPJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MVWyOVM4PTJ5MR?=
U87MG-luc2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDTN4hVOTByLUSwNEDPxE1? MnfpO|IwQTZiaB?= NF\oWpV1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= M4XyOVI2Ozd3Mkex
U87 NYC1UZV3TnWwY4Tpc44hSXO|YYm= MmrGNlAxKM7:TR?= NVrwWINRPDhiaB?= NV;TO4NrcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= M{XjRVI2OzN5N{Kx
U251 MYXGeY5kfGmxbjDBd5NigQ>? MnPtNlAxKM7:TR?= MkjtOFghcA>? MkPMbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? MmG4NlU{Ozd5MkG=
A172 NVGxUZR4TnWwY4Tpc44hSXO|YYm= MXSyNFAh|ryP NVm0XI5TPDhiaB?= NEKyeFhqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w MlzmNlU{Ozd5MkG=
U251 MVTGeY5kfGmxbjDBd5NigQ>? NF;WZ3YzODBizszN M3TPeVQ5KGh? Mn;xbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MVuyOVM{Pzd{MR?=
A172 M2fZVmZ2dmO2aX;uJGF{e2G7 NWKzRW9qOjByIN88US=> MnTyOFghcA>? M4TFOolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? NUiyXYI4OjV|M{e3NlE>
U87 NHXSWWVHfW6ldHnvckBCe3OjeR?= NXzoSnZ4OjByIN88US=> MkfYNlQwPzJxMUKwJIg> NHK2OJFqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? MU[yOVM{Pzd{MR?=
U251 MUXGeY5kfGmxbjDBd5NigQ>? NVK0N41tOjByIN88US=> NVfDeXBsOjRxN{KvNVIxKGh? MlzJbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 M1;2NlI2OzN5N{Kx
A172 Mm\jSpVv[3Srb36gRZN{[Xl? NWj2b3pyOjByIN88US=> NHixN5gzPC95Mj:xNlAhcA>? NVXyOWJQcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MXyyOVM{Pzd{MR?=
SNB19V NEnDbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC3JIQ> NXe3N25lTE2VTx?= MXrHTVUxRTN3LkhCtVEzKM7:TR?= NXvkXpV6OjV{N{e0OFE>
SNB19M MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorDO{Bl MmW3SG1UVw>? Mn6xS2k2OD12NkmuPeKyQDhizszN NFvVTFAzPTJ5N{S0NS=>
SNB19VR NWPoOHprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTVcllHPyCm MY\EUXNQ M3fxO2dKPTB;MkiwMlLDuTF6IN88US=> NWLLSI8zOjV{N{e0OFE>
U373V MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL0O{Bl MXvEUXNQ NXnkPWZ5T0l3ME22PE4xyrF|MjFOwG0> Mn;FNlUzPzd2NEG=
U373M NUjyN2VZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G5Tlch\A>? NET0cXdFVVOR MkG0S2k2OD1|NkiuO:KyQDZizszN M1HydFI2Ojd5NESx
U373VR MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHKO{Bl MV3EUXNQ MXPHTVUxRTJ6OD64xtE{OyEQvF2= M4Pt[lI2Ojd5NESx
U87MG MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHtT5hlPyCm NIWycohFVVOR NHr1OFdIUTVyPUO4MlPDuTJyIN88US=> MV:yOVI4PzR2MR?=
HCT116 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T0V|ch\A>? M371U2ROW09? MVvHTVUxRTV5OT65xtE{OiEQvF2= MmLWNlUzPzd2NEG=
DLD1 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnHbZg4KGR? Mlv0SG1UVw>? NEjB[JJIUTVyPUWwNU41yrF7MzFOwG0> NGLEN4MzPTJ5N{S0NS=>
MRC5 NF\DNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGexW4c4KGR? NWLnVI1bTE2VTx?= M{TyfGdKPTB;NES5MlTDuThizszN MWGyOVI4PzR2MR?=
SNB19V  NHzhbHRHfW6ldHnvckBCe3OjeR?= M3nEWVExOCEQvF5CpHROYg>? MXSwMVczKGh? M33iOYlv[3KnYYPld{DPu0h{QWig[ZhxemW|c3nvckBj\XS5ZXXuJFE3KGGwZDC3NkBp NUDCXIwzOjV{N{e0OFE>
T98G  NUTJV4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5dGtGPS9zMD:xOUDPxE1? MYqyOOKhcA>? NHe4VXpqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> MmGwNlUzPjJ7NkG=
U251  MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX61M|ExNzF3IN88US=> NIHFfW4zPMLiaB?= MnXBbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= NH33dYIzPTJ4Mkm2NS=>
T98G  NVzrWpExTnWwY4Tpc44hSXO|YYm= NED0cW4yPSEQvF2= MWWyOOKhcA>? Mn[4bY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| M2fwUVI2OjZ{OU[x
U251  Mlm3SpVv[3Srb36gRZN{[Xl? MYOxOUDPxE1? NV:4SpNuOjUEoHi= NX\lTGpycW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz NWTkRldWOjV{NkK5OlE>
U-87 MG NHHxT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTtb|M4OiCq NITmXYdKSzVyPUCuPVMhdU4EoB?= M2TM[lI2OjR3M{Oy
U-118 MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f1[VczKGh? MVHJR|UxRTFwMEWgcW3DqA>? MXyyOVI1PTN|Mh?=
U87 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWeyOEBp M2HD[WlEPTB;Mk[wMlM1KM7:TdMg NHvyXJgzPTF5M{KzNy=>
U87 GSLCs NXHubINkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfnSoQzPCCq MYLJR|UxRTd4Nj6xNUDPxE4EoB?= Ml7WNlUyPzN{M{O=
U87MG NY\EUYFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yyWVczKGh? NYiybGdnUUN3ME2xOU43OjVizszNxsA> NEG5SY4zPTB3MEmxOS=>
U251 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTNXms2OTByLUSwNEDPxE1? Ml;TOFghcA>? NXe2WGhHTE2VTx?= NITzcYpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnHnNlQ3OjN5M{[=
U87 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13BclExOC12MECg{txO NWf5U3AzPDhiaB?= M3vGU2ROW09? MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHfE[4wzPDZ{M{ezOi=>
MDA-MB-231-br NH7mUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LteFAuOTBizszN MnXDOFghcA>? NVq3XWR6TE2VTx?= M4jCUIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3Ha[lI1PjJ|N{O2
HCC-1937 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK5NnIxNTNyMDFOwG0> MVm0PEBp MXvEUXNQ NFzPXVBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF\JWoEzPDZ{M{ezOi=>
MDA-MB-231 NEHlc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELJSJExNTRyIN88US=> MmX4OFghcA>? NVfQdYxwTE2VTx?= MmPBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVvCVoplOjR4MkO3N|Y>
MDA-MB-468 M3L0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSwMVUxOCEQvF2= MlnBOFghcA>? MXXEUXNQ MmrtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYLWeI5JOjR4MkO3N|Y>
T47D NWn4fGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfvepQxNTFyMDFOwG0> MmfnOFghcA>? NXnsdHh7TE2VTx?= M1:5WYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH63R2QzPDZ{M{ezOi=>
MCF7 M1\QZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoewNE0yODByIN88US=> NVz4cmxUPDhiaB?= NIfDOVNFVVOR MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mke3NlQ3OjN5M{[=
Hs683 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3viOlAuOTByMDFOwG0> NXvPeZBTQTZiaB?= MYrJR|UxRTF{OD65JO69VQ>? NUO1O2o4OjR2OUW5NFc>
U87 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrwNE0yODByIN88US=> NEfwRVY6PiCq NF;NR4FKSzVyPUG4MlQ2KM7:TR?= M3vhSFI1PDl3OUC3
LNZ308 NWjs[29QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfWNE0yODByIN88US=> NWH4dYZ4QTZiaB?= NWTieYNMUUN3ME2zNlYvPyEQvF2= MlPpNlQ1QTV7MEe=
U87 MYnBdI9xfG:|aYOgRZN{[Xl? MnXjNVAxKM7:TR?= MUm0PEBp M3ztbWROW09? MVLpcoNz\WG|ZYOgeIhmKGOjc4Dhd4UuOy95IHHjeIl3cXS7 M2TGUlI1PDhzNUi2
U251  M3qzd2Fxd3C2b4Ppd{BCe3OjeR?= M1j3VFExOCEQvF2= MXm0PEBp MkHYSG1UVw>? NFrlOo1qdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 MXuyOFQ5OTV6Nh?=
U251 MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KRmd3OjRiaB?= M{fHTGlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN NXf3T2VbOjR|Mk[5OVQ>
U251 M17yN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LYclQ5KGh? MlSyTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= MnHzNlQ{OjZ7NUS=
U251 NYLqS5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK3NkBp NHT2eGpKSzVyPUeyMlQz6oDLwsJihKkyNjR3IN88US=> M4DmTVI1OzJ4OUW0
U251 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:5OkBp MmDETWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= MlT1NlQ{OjZ7NUS=
T98G NYX6SFZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSwMVc2OCEQvF2= MWC3Nk86PiCq Ml\PbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIjv[VIzPDN{NEC4NC=>
U251-MG NIPlXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[wMVgxOCEQvF2= M2C0XFczKGh? MYHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NVf1b4l7OjRyOUO2N|A>
D54-MG M{jyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXSOJNtOC16MECg{txO MkXzO|IhcA>? M3HNcYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MmP2NlQxQTN4M{C=
SHG-44 NIrF[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7ucI1XOTBvMkCwJO69VQ>? NYnjRVFqQTZiaB?= Ml65TWM2OD17LkezJOKyKDJwMUKg{txO MVGyOFA3PTV4OR?=
U373  M2rEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC1RmwyOC1{MECg{txO Mn2yPVYhcA>? MYHJR|UxRTFyLkGzJOKyKDFwMEKg{txO NYPsPIhpOjRyNkW1Olk>
HT-29  NFLoSVRHfW6ldHnvckBCe3OjeR?= M2jXclUxOCEQvF2= MmLINlQwPDhiaB?= MmKy[Y5p[W6lZYOgeIhmKGyndnXsd{Bw\iEQsz3INmFZyqB? M{HFcVI1ODN6ME[4
PC-3  NWTBZpdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq4NE0zPSEQvF2= M2PUcVQ5KGh? MnjObY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m M4P3WlI{PzR4OUO0
PC-3  M{OyOWFxd3C2b4Ppd{BCe3OjeR?= NUXOcXYxOjVizszN MojSOFghcA>? NIDtZmxqdmS3Y3XzJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> MV6yN|c1Pjl|NB?=
T98G MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[ycWMxPTBvNECwJO69VQ>? M3nZbVE1PCCq NXG0T4MycW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NXXkTWVSOjN5MUW0PVk>
U87-MG NUXqWm41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknnNVAxKML3TR?= MXW3NkBp M{XKSYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? NFvaWnczOzZ7Nke4PC=>
U251-MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETHO3YyODBiwsXN NUTzdGlRPzJiaB?= M3XkVIlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? MmTDNlM3QTZ5OEi=
LNT-229 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLjVJU{NTFyMDFOwG0> MVuyOEBp NXTvT|JbcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGnUSnAzOzZ4N{[zNi=>
T98G M{ntSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rrd|ExNTdyMDFOwG0> M2[zZlI1KGh? MVXpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn7yNlM3Pjd4M{K=
U87  NGnvdWVHfW6ldHnvckBCe3OjeR?= NIC0[W4yODBiwsXN MlvzN{Bp NEXxZmpmdGW4YYTld{B1cGVibHX2[Yx{KG:oIIDDbIsyKGGwZDDwR4hsOg>? NXL0d3loOjN4Nke0Olk>
HCT116 M1nmRWZ2dmO2aX;uJGF{e2G7 MX[xNFAhyrWP NHm5bWc{KGh? NIrmTlRqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= MXWyN|Y3PzR4OR?=
HCT3-6 NELXepJHfW6ldHnvckBCe3OjeR?= M2XhUFExOCEEtV2= M3jPW|MhcA>? NEDIXFVqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= M3fUTVI{PjZ5NE[5
U-87  NX\IU|ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL6NE01OCEQvF2= MXixNkBl M2PlNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUKyN|Y1PTd{OR?=
U-87  NUDORW0ySXCxcITvd4l{KEG|c3H5 NWGwbIJ5OC12MDFOwG0> NGj4eG0{NzZiZB?= NXfwe|VEcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NELuZlczOzZ2NUeyPS=>
U-87  NHv5cWxHfW6ldHnvckBCe3OjeR?= NELNfG8xNTRyIN88US=> NHW2R2U{NzZiZB?= M3HLXYlv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M4fPSVI{PjR3N{K5
GB-SCC010 M3jwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX0OEBl NX;tTHRoUUN3ME2yNlYh|ryP MXuyN|YyOjd3NR?=
GB-SCC026 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXkOEBl MXLJR|UxRTV|LkGg{txO NWTHT4c1OjN4MUK3OVU>
GB-SCC028 NUTuVYVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK1S4E1KGR? M4XKVmlEPTB;MU[3JO69VQ>? MmnHNlM3OTJ5NUW=
U87 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP3fmU1KGR? NYroOWRJUUN3ME20OU4zKM7:TR?= MmfCNlM3OTJ5NUW=
U87 stem cell MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS4OEBl NH70TFNKSzVyPU[2Mlch|ryP NUnHUHB{OjN4MUK3OVU>

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02977780 Recruiting Glioblastoma Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology, Inc.|Accelerate Brain Cancer Cure February 9, 2017 Phase 2
NCT02689336 Recruiting Glioma|Rhabdomyosarcoma|Osteosarcoma|Medulloblastoma|Neuroectodermal Tumor|Ependymoma|Ewings Sarcoma|Wilms Tumor Washington University School of Medicine August 6, 2016 Phase 2
NCT02455557 Recruiting Glioblastoma|Gliosarcoma Roswell Park Cancer Institute|National Cancer Institute (NCI) May 5, 2015 Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT03018288 Not yet recruiting Glioblastoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 3, 2017 Phase 2
NCT02766270 Recruiting Grade II/III Glioma Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Beijing Shijitan Hospital September 26, 2016 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID